Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki M A, Cowan J
Record ID 32004000181
Authors' objectives: The aim of this review was to evaluate the use of pioglitazone and rosiglitazone, in terms of both clinical and cost-effectiveness in the treatment of type 2 diabetes.
Authors' recommendations: The clinical evidence available showed that glitazones reduce glycosylated haemoglobin by approximately 1%, and are more effective at higher doses than at lower doses. Glitazone treatment is associated with weight gain. No published data were available on the long-term effects of glitazone use. No prospective randomised controlled trials (RCTs) were found comparing pioglitazone to rosiglitazone, but the available evidence indicated that the two treatments had similar effects.
Authors' methods: Systematic review, Economic evaluation
Project Status: Completed
URL for project:
Year Published: 2004
URL for published report: n/a
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Costs and Cost Analysis
  • Diabetes Mellitus, Type 2
  • Hypoglycemic Agents
  • Thiazolidinediones
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
Contact Email:
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.